Novo Nordisk A/S (NVO), a global healthcare company, announced today a strategic partnership with OpenAI to improve and accelerate delivery of treatments.
The partnership is planned to apply artificial intelligence (AI) to analyze complex datasets, identify promising drug candidates, and reduce the time required to move between research and patients.
OpenAI will contribute to Novo Nordisk by upskilling its workforce, improving efficiency in manufacturing, supply chain, distribution and corporate operations. Additionally, Open AI will launch pilot programs across research and development, manufacturing, and commercial operations, with full integration intended by the end of 2026.
The company noted that the partnership would be applied with strict data governance and human oversight to ensure strict and ethical use of information.
NVO closed Monday at $37.98, up 1.23%. In the premarket shares are trading at $39.05, up 2.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.